KRAS (KRAS proto-oncogene GTPase)

Combining SDUY104 with an ERK inhibitor Ulixertinib produced synergistic antiproliferative activity via enhanced MAPK suppression. In a PANC-1 xenograft model, combination of SDUY104 with BKM-120 exhibited superior antitumor activity compared to either monotherapy. Collectively, this study identifies a potent SHP2 allosteric inhibitor and delineates a critical compensatory signaling mechanism underlying resistance to SHP2-targeted therapy, providing proof-of-concept support for pancreatic cancer treatment.

Our findings emphasize that when imaging or cytology suggests multiorigin components, clinicians should pursue thorough intraoperative exploration, multisite biopsies, and prophylactic appendectomy. Ultimately, the management of such patients requires highly individualized surgical and chemotherapeutic strategies that account for the divergent biological behaviors and therapeutic sensitivities of both HGSOC and well-differentiated appendiceal mucinous adenocarcinoma to optimize oncological outcomes.

Neoadjuvant nivolumab combined with platinum-based chemotherapy demonstrates favorable pharmacological efficacy, manageable toxicity and biomarker-driven therapeutic response in resectable NSCLC under real-world clinical conditions. These findings support the role of personalized immunopharmacotherapy and reinforce the clinical relevance of biomarker-guided drug selection in modern pharmaceutical oncology.

P1, N=58, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jun 2027 --> Mar 2027 | Trial primary completion date: Jun 2027 --> Mar 2027

P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028

However, the associated adverse effects of these agents, along with drug resistance, remain a challenge. In this review, we discuss targeted therapies for lung cancer, their efficacy, clinical trials, adverse effects, mechanisms of resistance, and future directions.

The procedure includes tissue perfusion, controlled enzymatic digestion, gentle mechanical dissociation, red blood cell lysis, filtration, and viability assessment, and achieves >85% viable cells prior to scRNA-seq. Finally, the tdTomato+ tumor cells are efficiently isolated by FACS and can be detected as distinct clusters by scRNA-seq using this protocol.

Future strategies should prioritize multicenter validation, integration of chronobiological profiling, and exploration of combination therapies. Cost-effectiveness analyses, awareness campaigns, and clinical drives to evaluate safety and adherence will be essential to establish trust and optimize outcomes.

AAV-mediated HOTAIR silencing represents a promising approach for modulating CRC-associated molecular pathways. Further mechanistic and functional investigations, including apoptosis assays and expanded cell line panels, are warranted to validate and extend these findings.

Adagrasib with ICI improved long-term survival and blocked CNS progression in dual extra- and intracranial BM models.  These findings support investigation of adagrasib with ICI in patients with KRASG12C-mutant BM.

Notably, YIYA stabilises KRAS by preventing its autophagy-mediated degradation, thereby sustaining a proliferative state. This study identifies YIYA as a glucose-responsive lncRNA that links KRAS signalling to metabolic reprogramming in PDAC.